PMID- 32671958
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 13
IP  - 2
DP  - 2021 Feb
TI  - Low serum levels of bone turnover markers are associated with the presence and 
      severity of diabetic retinopathy in patients with type 2 diabetes mellitus.
PG  - 111-123
LID - 10.1111/1753-0407.13089 [doi]
AB  - BACKGROUND: Accumulating evidence demonstrates an association of type 2 diabetes 
      mellitus (T2DM) and its microvascular complications with increased fracture risk. 
      In this study, we aimed to evaluate the relationships between serum 
      concentrations of bone turnover markers and the presence and/or severity of 
      diabetic retinopathy (DR) among patients with T2DM. METHODS: A total of 285 
      patients with T2DM comprising 168 patients without DR and 117 patients with DR 
      were enrolled in the cross-sectional study. In the latter group, patients were 
      further divided into patients of mild and severe DR stages. The biochemical 
      parameters and bone turnover markers were determined in all participants. 
      RESULTS: This study found that serum levels of procollagen type 1 N-terminal 
      propeptide (P1NP), a bone formation marker, and the bone resorption marker serum 
      beta-cross-linked C-telopeptide of type I collagen (beta-CTX) were more decreased in 
      diabetic patients with DR than in those without DR, with differences remaining 
      significant (P < .05) in multivariate linear regression models after adjustments 
      for multiple confounding factors. Osteocalcin and beta-CTX levels were further 
      reduced along with the severity of DR among participants with DR. Moreover, 
      multivariate logistic regression analysis revealed that lower serum levels of 
      P1NP and beta-CTX were associated with higher odds for the presence of DR, while 
      beta-CTX was associated with the severity of DR. CONCLUSION: Our results suggest 
      that the development of DR might be involved in the progression of T2DM-induced 
      deficits in bone formation and resorption or vice versa. Follow-up studies and 
      further research are necessary to validate the associations and elucidate the 
      underlying mechanisms.
CI  - (c) 2020 Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John 
      Wiley & Sons Australia, Ltd.
FAU - An, Yaxin
AU  - An Y
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
FAU - Liu, Simo
AU  - Liu S
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
FAU - Wang, Wenbo
AU  - Wang W
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
FAU - Dong, Huan
AU  - Dong H
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
FAU - Zhao, Wenying
AU  - Zhao W
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
FAU - Ke, Jing
AU  - Ke J
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
FAU - Zhao, Dong
AU  - Zhao D
AUID- ORCID: 0000-0002-9847-5439
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Biomarkers)
RN  - 0 (Collagen Type I)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Procollagen)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - 0 (procollagen Type I N-terminal peptide)
RN  - 104982-03-8 (Osteocalcin)
SB  - IM
MH  - Biomarkers/blood
MH  - Bone Remodeling/*physiology
MH  - Collagen Type I/*blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Diabetic Retinopathy/blood/*diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteocalcin/*blood
MH  - Peptide Fragments/*blood
MH  - Peptides/*blood
MH  - Procollagen/*blood
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - 2型糖尿病
OT  - bone turnover markers
OT  - diabetic retinopathy
OT  - type 2 diabetes mellitus
OT  - 糖尿病视网膜病变
OT  - 骨转化标志物
EDAT- 2020/07/17 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - 10.1111/1753-0407.13089 [doi]
PST - ppublish
SO  - J Diabetes. 2021 Feb;13(2):111-123. doi: 10.1111/1753-0407.13089. Epub 2020 Oct 
      8.